176 related articles for article (PubMed ID: 32029905)
21. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
Somnay Y; Simon K; Harrison AD; Kunnimalaiyaan S; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2013 Jan; 24(1):66-72. PubMed ID: 23147412
[TBL] [Abstract][Full Text] [Related]
22. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
[TBL] [Abstract][Full Text] [Related]
23. Botulinum neurotoxin type A in facial aesthetics.
De Boulle KL
Expert Opin Pharmacother; 2007 Jun; 8(8):1059-72. PubMed ID: 17516871
[TBL] [Abstract][Full Text] [Related]
24. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.
Wang J; Zurawski TH; Meng J; Lawrence G; Olango WM; Finn DP; Wheeler L; Dolly JO
J Biol Chem; 2011 Feb; 286(8):6375-85. PubMed ID: 21138836
[TBL] [Abstract][Full Text] [Related]
25. Presynaptic targeting of botulinum neurotoxin type A requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry.
Joensuu M; Syed P; Saber SH; Lanoue V; Wallis TP; Rae J; Blum A; Gormal RS; Small C; Sanders S; Jiang A; Mahrhold S; Krez N; Cousin MA; Cooper-White R; Cooper-White JJ; Collins BM; Parton RG; Balistreri G; Rummel A; Meunier FA
EMBO J; 2023 Jul; 42(13):e112095. PubMed ID: 37226896
[TBL] [Abstract][Full Text] [Related]
26. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
27. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.
Peng L; Tepp WH; Johnson EA; Dong M
PLoS Pathog; 2011 Mar; 7(3):e1002008. PubMed ID: 21483489
[TBL] [Abstract][Full Text] [Related]
28. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
30. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
Front Immunol; 2018; 9():1799. PubMed ID: 30123222
[TBL] [Abstract][Full Text] [Related]
31. Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.
Szlachcic A; Zakrzewska M; Lobocki M; Jakimowicz P; Otlewski J
Drug Des Devel Ther; 2016; 10():2547-60. PubMed ID: 27563235
[TBL] [Abstract][Full Text] [Related]
32. Botulinum neurotoxin serotypes A and C do not affect motor units survival in humans: an electrophysiological study by motor units counting.
Eleopra R; Tugnoli V; Quatrale R; Gastaldo E; Rossetto O; De Grandis D; Montecucco C
Clin Neurophysiol; 2002 Aug; 113(8):1258-64. PubMed ID: 12140005
[TBL] [Abstract][Full Text] [Related]
33. Current and potential urological applications of botulinum toxin A.
Jiang YH; Liao CH; Kuo HC
Nat Rev Urol; 2015 Sep; 12(9):519-33. PubMed ID: 26260879
[TBL] [Abstract][Full Text] [Related]
34. The evolution of botulinum neurotoxin type A for cosmetic applications.
Carruthers J; Carruthers A
J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
[TBL] [Abstract][Full Text] [Related]
35. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
36. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.
Oshima M; Deitiker P; Jankovic J; Atassi MZ
Immunol Invest; 2018 Jan; 47(1):18-39. PubMed ID: 28891721
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.
Truong M; Cook MR; Pinchot SN; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2011 May; 18(5):1506-11. PubMed ID: 21184191
[TBL] [Abstract][Full Text] [Related]
38. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
[TBL] [Abstract][Full Text] [Related]
39. Pharmacology of botulinum toxin: differences between type A preparations.
Rosales RL; Bigalke H; Dressler D
Eur J Neurol; 2006 Feb; 13 Suppl 1():2-10. PubMed ID: 16417591
[TBL] [Abstract][Full Text] [Related]
40. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models.
Marinelli S; Luvisetto S; Cobianchi S; Makuch W; Obara I; Mezzaroma E; Caruso M; Straface E; Przewlocka B; Pavone F
Neuroscience; 2010 Nov; 171(1):316-28. PubMed ID: 20826198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
